Eventbrite (NYSE:EB) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 16.67 percent decrease over losses of $(0.18) per share from the sameEventbrite (NYSE:EB) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 16.67 percent decrease over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $65.47 million which missed the analyst consensus estimate of $67.53 million by 3.05 percent. This is a 22.68 percent increase over sales of $53.37 million the same period last year.
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).
